Skip to content

The Leuven Longitudinal Late-Life Depression Study

The Leuven Longitudinal Late-Life Depression Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07768098
Acronym
L4D
Enrollment
178
Registered
2026-08-17
Start date
2026-07-30
Completion date
2029-12-31
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late Life Depression (LLD)

Brief summary

The goal of this observational study is to learn about the long-term effects of late-life depression (LLD) in adults aged 60 and older. LLD is depression that begins for the first time later in life. Patients with this condition may feel sad for a long time or lose interest in activities they used to enjoy. They may also have problems with sleep, energy, or concentration. In some patients, this depression comes with changes in thinking and memory, which may be linked to a higher risk of dementia. The investigators believe that changes in the brain play a role in this condition. The main questions this study aims to answer are: Do patients with late-life depression have a higher risk of memory decline, dementia, return of depression, hospital stays, or death compared to healthy people? Can brain scans and blood tests help predict how the illness will develop over time? The investigators will compare patients with late-life depression to healthy people of the same age and sex. This will help clarify how the illness develops over several years. This is a follow-up study, which means no new treatment is being tested. The investigators will recruit participants from previous studies, drawn from two cohorts with a mean follow-up time since inclusion of 12 years and 6 years. The investigators collect information about health, memory, and mood, and compare it with earlier measurements. To do this, the investigators use existing information from past studies, medical records, brain scans, and blood samples. Participants can take part if they: Are at least 60 years old Took part in one of the earlier studies Give written permission to join Participants may be asked to: Have a conversation and take memory tests Give a blood sample Have a brain scan These tests can take place in the hospital or at the participant's home. If a participant does not want to do the tests again, the investigators can ask their family doctor for important health information, with the participant's permission.

Interventions

None listed

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. * At least 18 years of age at the time of signing the Informed Consent Form (ICF). * Participants were included in the previous studies.

Exclusion criteria

* Not applicable, since participants who met any

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants with DementiaFrom enrollment in the initial cross-sectional study to the follow-up assessment, an average of 12 years for cohort 1 and 6 years for cohort 2Participants with a MMSE score lower or equal to 10, and a CDR scale score higher or equal to 2, will be classified as having dementia.
Number of Participants Who DiedFrom enrollment in the initial cross-sectional study until date of death from any cause, assessed up to 12 years for cohort 1 and up to 6 years for cohort 2.

Secondary

MeasureTime frameDescription
Rate of depressive episodesFrom enrollment in the initial cross-sectional study to the follow-up assessment, an average of 12 years for cohort 1 and 6 years for cohort 2. If deceased, up until passing away.Hospitalisations for depression, referrals to psychotherapy or psychiatry, suicide attempts

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026